Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).

Date Range:

	Revance Therapeutics	Morphic	Atea Pharmaceuticals	Cytokinetics	Ironwood Pharmaceuticals
Symbol	NASDAQ:RVNC	NASDAQ:MORF	NASDAQ:AVIR	NASDAQ:CYTK	NASDAQ:IRWD
Price Information
Current Price	$29.72	$64.71	$31.97	$33.61	$12.99
50-Day Moving Average	$27.90	$60.83	$28.24	$30.98	$12.97
52-Week Low	$22.89	$24.52	$18.72	$14.71	$8.63
52-Week High	$33.83	$93.00	$94.17	$34.45	$14.27
MarketRank™
Overall Score	2.2	2.6	2.6	2.4	1.8
Analysis Score	3.5	3.5	3.5	4.5	1.1
Community Score	4.5	4.3	5.0	5.0	4.1
Dividend Score	0.0	0.0	0.0	0.0	0.0
Ownership Score	2.5	5.0	2.5	2.5	0.8
Earnings & Valuation Score	0.6	0.0	1.9	0.0	3.1
Analyst Ratings
Consensus Recommendation	Buy	Buy	Buy	Buy	Hold
Consensus Price Target	$37.25	$85.00	$55.75	$43.09	$12.00
% Upside from Price Target	25.34% upside	31.36% upside	74.38% upside	28.21% upside	-7.62% downside
Trade Information
Market Cap	$2.13 billion	$2.36 billion	$2.40 billion	$2.81 billion	$2.12 billion
Beta	1.24	1.2	N/A	1.41	1.37
Average Volume	421,589	274,176	1,504,603	1,218,402	1,938,897
Sales & Book Value
Annual Revenue	$15.32 million	$44.94 million	$48.63 million	$55.83 million	$389.52 million
Price / Sales	139.35	52.49	54.42	50.28	5.43
Cashflow	N/A	N/A	N/A	N/A	$0.87 per share
Price / Cash	N/A	N/A	N/A	N/A	14.93
Book Value	$5.62 per share	$4.66 per share	$6.63 per share	$1.60 per share	$0.39 per share
Price / Book	5.29	13.89	4.82	21.01	33.31
Profitability
Net Income	$-282,090,000.00	$-45,000,000.00	$-10,950,000.00	$-127,290,000.00	$106.18 million
EPS	($4.86)	($1.47)	($0.51)	($1.97)	$0.79
Trailing P/E Ratio	N/A	N/A	N/A	N/A	4.16
Forward P/E Ratio	N/A	N/A	2.23	N/A	7.55
P/E Growth	N/A	N/A	N/A	N/A	N/A
Net Margins	-644.56%	-158.61%	N/A	-269.48%	123.20%
Return on Equity (ROE)	-103.06%	-24.79%	N/A	-179.39%	109.74%
Return on Assets (ROA)	-44.14%	-18.05%	N/A	-28.99%	28.51%
Dividend
Annual Payout	N/A	N/A	N/A	N/A	N/A
Dividend Yield	N/A	N/A	N/A	N/A	N/A
Three-Year Dividend Growth	N/A	N/A	N/A	N/A	N/A
Payout Ratio	N/A	N/A	N/A	N/A	N/A
Years of Consecutive Dividend Growth	N/A	N/A	N/A	N/A	N/A
Debt
Debt-to-Equity Ratio	1.50%	N/A	N/A	7.76%	0.64%
Current Ratio	6.09%	12.51%	3.18%	5.90%	4.62%
Quick Ratio	6.00%	12.51%	3.18%	5.90%	4.62%
Ownership Information
Institutional Ownership Percentage	75.29%	71.77%	70.41%	90.54%	N/A
Insider Ownership Percentage	4.40%	31.40%	18.40%	5.70%	12.60%
Miscellaneous
Employees	470	89	39	184	232
Shares Outstanding	71.83 million	36.45 million	82.78 million	83.51 million	162.90 million
Next Earnings Date	11/8/2021 (Estimated)	11/8/2021 (Estimated)	12/9/2021 (Estimated)	11/3/2021 (Estimated)	11/4/2021 (Estimated)
Optionable	Optionable	Not Optionable	Not Optionable	Optionable	Optionable

Source	Headline
	Interesting IRWD Put And Call Options For May 2022 nasdaq.com - September 17 at 3:46 PM
	Oversold Conditions For Ironwood Pharmaceuticals (IRWD) nasdaq.com - September 14 at 8:57 PM
	Ironwood Pharmaceuticals Inc (IRWD): Price Now Near $12.4; Daily Chart Shows An Uptrend on 100 Day Basis etfdailynews.com - September 10 at 4:48 PM
	Ironwood Pharmaceuticals (NASDAQ:IRWD) Shares Gap Down to $12.56 americanbankingnews.com - September 8 at 10:58 AM
	Ironwood Pharma: FDA Approves Revised Label For LINZESS - Quick Facts nasdaq.com - August 26 at 10:41 AM
	Ironwood Irritable-Bowel Drug Gets Revised FDA Warning Label finance.yahoo.com - August 26 at 10:41 AM
	Ironwood Pharmaceuticals Announces FDA Approval of Revised LINZESS® (linaclotide) Label finance.yahoo.com - August 26 at 10:41 AM
	Sarissa Capital Management LP Buys Alkermes PLC, Vor Biopharma Inc, Sells BioCryst ... uk.finance.yahoo.com - August 24 at 3:45 PM
	Ironwood Pharmaceuticals, Inc. Class A Common Stock (IRWD) nasdaq.com - August 24 at 9:17 AM
	Noteworthy Tuesday Option Activity: PRPL, IRWD, STLD nasdaq.com - August 10 at 5:45 PM
	Ironwood's (IRWD) Q2 Earnings Beat, 2021 Guidance Raised finance.yahoo.com - August 6 at 1:56 PM
	Ironwood Pharmaceuticals, inc (IRWD) Q2 2021 Earnings Call Transcript finance.yahoo.com - August 5 at 7:46 PM
	Ironwood: Q2 Earnings Snapshot sfgate.com - August 5 at 9:45 AM
	Ironwood Pharmaceuticals Reports Strong Second-Quarter 2021 Results, Raises Full-Year Guidance finance.yahoo.com - August 5 at 9:45 AM
	Why Ironwood (IRWD) Could Beat Earnings Estimates Again msn.com - August 4 at 1:30 PM
	Ironwood Pharmaceuticals Appoints John Minardo as Chief Legal Officer finance.yahoo.com - August 3 at 12:05 PM
	Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD) Is An Exciting Stock To Watch. stocksregister.com - July 23 at 12:54 PM
	Ironwood Pharmaceuticals to Host Second Quarter 2021 Investor Update Call finance.yahoo.com - July 22 at 8:01 PM
	Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD): How Much Is It Worth And What Should Investors Do? marketingsentinel.com - July 22 at 3:00 PM
	We Think Ironwood Pharmaceuticals (NASDAQ:IRWD) Can Manage Its Debt With Ease finance.yahoo.com - July 21 at 1:10 PM
	Ironwood Pharmaceuticals Inc. [IRWD] gain 9.13% so far this year. What now? dbtnews.com - July 13 at 11:53 AM
	Is Ironwood Pharmaceuticals, Inc. (IRWD) A Good Stock To Buy? finance.yahoo.com - July 12 at 6:07 PM
	12-month price target for Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) now sits at $15 marketingsentinel.com - July 8 at 1:36 PM
	Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD) Recovered 34.12% From The 52-Week Low, And Now It’s 12.47% YTD – This Is What You Do Now marketingsentinel.com - June 25 at 2:09 PM
	For Ironwood Pharmaceuticals Inc. [IRWD], Analyst sees a drop to $9. What next? dbtnews.com - June 24 at 12:43 AM

Date	Company	Brokerage	Action
9/9/2021	Atea Pharmaceuticals	SVB Leerink	Initiated Coverage
9/7/2021	Cytokinetics	Barclays	Boost Price Target
8/18/2021	Atea Pharmaceuticals	Morgan Stanley	Boost Price Target
8/9/2021	Cytokinetics	Piper Sandler	Lower Price Target
8/6/2021	Revance Therapeutics	Barclays	Boost Price Target
8/6/2021	Cytokinetics	HC Wainwright	Boost Price Target
7/20/2021	Cytokinetics	Cantor Fitzgerald	Boost Price Target
7/20/2021	Cytokinetics	Barclays	Boost Price Target
7/19/2021	Cytokinetics	JMP Securities	Boost Price Target
7/19/2021	Cytokinetics	Raymond James	Boost Price Target
7/19/2021	Cytokinetics	Piper Sandler	Boost Price Target
7/19/2021	Cytokinetics	HC Wainwright	Boost Price Target
7/19/2021	Cytokinetics	Needham & Company LLC	Boost Price Target
7/16/2021	Ironwood Pharmaceuticals	Morgan Stanley	Boost Price Target
7/6/2021	Ironwood Pharmaceuticals	Northland Securities	Reiterated Rating
7/1/2021	Cytokinetics	Mizuho	Initiated Coverage
6/3/2021	Atea Pharmaceuticals	Morgan Stanley	Lower Price Target
5/11/2021	Revance Therapeutics	Mizuho	Lower Price Target
5/11/2021	Cytokinetics	Mizuho	Boost Price Target
5/3/2021	Morphic	BMO Capital Markets	Lower Price Target
4/23/2021	Revance Therapeutics	Mizuho	Boost Price Target
4/19/2021	Cytokinetics	Morgan Stanley	Boost Price Target
4/14/2021	Revance Therapeutics	Needham & Company LLC	Reiterated Rating
4/6/2021	Atea Pharmaceuticals	Morgan Stanley	Boost Price Target
3/11/2021	Cytokinetics	Wolfe Research	Initiated Coverage
3/1/2021	Morphic	Wells Fargo & Company	Boost Price Target
2/25/2021	Ironwood Pharmaceuticals	Morgan Stanley	Lower Price Target
2/23/2021	Revance Therapeutics	Mizuho	Boost Price Target
2/23/2021	Revance Therapeutics	HC Wainwright	Boost Price Target
2/18/2021	Cytokinetics	Barclays	Initiated Coverage
2/2/2021	Morphic	Royal Bank of Canada	Boost Price Target
1/29/2021	Atea Pharmaceuticals	JPMorgan Chase & Co.	Boost Price Target
1/20/2021	Cytokinetics	HC Wainwright	Boost Price Target
1/8/2021	Revance Therapeutics	Needham & Company LLC	Boost Price Target
12/16/2020	Cytokinetics	Morgan Stanley	Boost Price Target
12/14/2020	Cytokinetics	Mizuho	Lower Price Target
11/24/2020	Atea Pharmaceuticals	Evercore ISI	Initiated Coverage
11/24/2020	Atea Pharmaceuticals	Morgan Stanley	Initiated Coverage
11/24/2020	Atea Pharmaceuticals	JPMorgan Chase & Co.	Initiated Coverage
11/24/2020	Atea Pharmaceuticals	William Blair	Initiated Coverage
11/24/2020	Cytokinetics	Raymond James	Reiterated Rating
11/23/2020	Cytokinetics	HC Wainwright	Lower Price Target
11/16/2020	Cytokinetics	Needham & Company LLC	Reiterated Rating
11/16/2020	Cytokinetics	Morgan Stanley	Lower Price Target
11/10/2020	Revance Therapeutics	Mizuho	Lower Price Target
11/6/2020	Ironwood Pharmaceuticals	Credit Suisse Group	Boost Price Target
11/6/2020	Ironwood Pharmaceuticals	Morgan Stanley	Boost Price Target
10/28/2020	Cytokinetics	The Goldman Sachs Group	Initiated Coverage
10/26/2020	Revance Therapeutics	Barclays	Boost Price Target
10/26/2020	Morphic	Royal Bank of Canada	Initiated Coverage
10/15/2020	Revance Therapeutics	Needham & Company LLC	Boost Price Target
10/15/2020	Revance Therapeutics	HC Wainwright	Boost Price Target
10/12/2020	Cytokinetics	Morgan Stanley	Lower Price Target
10/8/2020	Cytokinetics	HC Wainwright	Lower Price Target
9/30/2020	Ironwood Pharmaceuticals	Wells Fargo & Company	Downgrade
9/28/2020	Revance Therapeutics	Barclays	Boost Price Target
8/26/2020	Morphic	BMO Capital Markets	Reiterated Rating
8/11/2020	Revance Therapeutics	Mizuho	Initiated Coverage
8/11/2020	Morphic	BMO Capital Markets	Boost Price Target
8/7/2020	Ironwood Pharmaceuticals	Morgan Stanley	Boost Price Target
8/3/2020	Ironwood Pharmaceuticals	Northland Securities	Reiterated Rating
7/15/2020	Ironwood Pharmaceuticals	Morgan Stanley	Lower Price Target
7/10/2020	Revance Therapeutics	HC Wainwright	Reiterated Rating
7/5/2020	Morphic	BMO Capital Markets	Reiterated Rating
6/17/2020	Ironwood Pharmaceuticals	Northland Securities	Initiated Coverage
6/2/2020	Revance Therapeutics	HC Wainwright	Reiterated Rating
6/1/2020	Ironwood Pharmaceuticals	Credit Suisse Group	Lower Price Target
5/20/2020	Revance Therapeutics	Mizuho	Reiterated Rating
5/11/2020	Ironwood Pharmaceuticals	HC Wainwright	Lower Price Target
5/7/2020	Ironwood Pharmaceuticals	Credit Suisse Group	Reiterated Rating
5/7/2020	Ironwood Pharmaceuticals	Morgan Stanley	Lower Price Target
4/30/2020	Ironwood Pharmaceuticals	Wells Fargo & Company	Lower Price Target
4/16/2020	Revance Therapeutics	Stifel Nicolaus	Lower Price Target
4/15/2020	Revance Therapeutics	Needham & Company LLC	Reiterated Rating
4/15/2020	Ironwood Pharmaceuticals	Morgan Stanley	Lower Price Target
4/1/2020	Revance Therapeutics	Mizuho	Reiterated Rating
3/27/2020	Revance Therapeutics	William Blair	Reiterated Rating
3/27/2020	Revance Therapeutics	HC Wainwright	Reiterated Rating
3/22/2020	Revance Therapeutics	The Goldman Sachs Group	Downgrade
3/5/2020	Morphic	Cowen	Reiterated Rating
2/26/2020	Revance Therapeutics	HC Wainwright	Reiterated Rating
2/25/2020	Revance Therapeutics	Piper Sandler	Boost Price Target
2/25/2020	Revance Therapeutics	Needham & Company LLC	Boost Price Target
1/28/2020	Ironwood Pharmaceuticals	HC Wainwright	Reiterated Rating
1/21/2020	Ironwood Pharmaceuticals	HC Wainwright	Reiterated Rating
9/13/2019	Ironwood Pharmaceuticals	Cowen	Set Price Target
8/13/2019	Morphic	BMO Capital Markets	Boost Price Target
8/12/2019	Morphic	Cowen	Reiterated Rating
7/31/2019	Ironwood Pharmaceuticals	Wedbush	Boost Price Target
7/22/2019	Morphic	Jefferies Financial Group	Initiated Coverage
7/22/2019	Morphic	Cowen	Initiated Coverage
7/22/2019	Morphic	Wells Fargo & Company	Initiated Coverage
7/22/2019	Morphic	BMO Capital Markets	Initiated Coverage
7/10/2019	Ironwood Pharmaceuticals	Credit Suisse Group	Reiterated Rating
6/24/2019	Ironwood Pharmaceuticals	HC Wainwright	Set Price Target
5/6/2019	Ironwood Pharmaceuticals	Wedbush	Reiterated Rating
5/3/2019	Ironwood Pharmaceuticals	Morgan Stanley	Set Price Target
5/2/2019	Ironwood Pharmaceuticals	Mizuho	Set Price Target

(Data available from 9/23/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Your Ultimate Investing Toolkit

Just $1.00 for your first month.

Compare Stocks

30 Days of MarketBeat All Access for $1.00

Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources